Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

R102

—

2e44d34b-edab-55a2-a63d-1fb14df10f79

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • CHOLESTEROL_HOMEOSTASIS+0.220
  • MYOGENESIS+0.210
  • ANGIOGENESIS+0.200
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
  • COAGULATION+0.170
  • APICAL_JUNCTION+0.160
  • ESTROGEN_RESPONSE_LATE+0.150
  • GLYCOLYSIS+0.150
  • KRAS_SIGNALING_DN+0.130
  • PEROXISOME+0.110

Top 10 suppressed

  • PROTEIN_SECRETION-0.390
  • KRAS_SIGNALING_UP-0.360
  • PANCREAS_BETA_CELLS-0.330
  • TGF_BETA_SIGNALING-0.330
  • MYC_TARGETS_V1-0.280
  • UNFOLDED_PROTEIN_RESPONSE-0.280
  • IL2_STAT5_SIGNALING-0.250
  • OXIDATIVE_PHOSPHORYLATION-0.200
  • ALLOGRAFT_REJECTION-0.180
  • TNFA_SIGNALING_VIA_NFKB-0.180

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1R18
bladder-landscape@3
——0.653
2MBCProject_3672_T1_RNA
breast-umap@18
—B0.629
3TCGA-69-7979-01A-11R-2187-07
lung-landscapes@6
—cohortA10.616
40e8bcafe-b201-4c66-8a0b-d89a4fd7c7ae
melanoma-umap@29
——0.610
5MNG841
mng-umap@100
——0.610
6BS_MKP2Y41Z
brain-umap@2
Posterior Fossa Ependymoma—0.609
7SJEPD031_R.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.605
806114a88-396c-4815-8949-910e46345e47
colon-landscapes@1
——0.596
9MNG559
mng-umap@100
——0.595
10BS_YE1MAQYJ
brain-umap@2
Spinal Cord Ependymoma—0.595

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
CHOLESTEROL_HOMEOSTASIS0.220Remibrutinib— uncovered
MYOGENESIS0.210Inavolisib— uncovered
ANGIOGENESIS0.200Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.200Inavolisib— uncovered
COAGULATION0.170Binimetinib— uncovered
APICAL_JUNCTION0.160Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.150Idelalisib— uncovered
GLYCOLYSIS0.150Inavolisib— uncovered
KRAS_SIGNALING_DN0.130Remibrutinib— uncovered
PEROXISOME0.110Idelalisib— uncovered
E2F_TARGETS0.090Inavolisib— uncovered
DNA_REPAIR0.080Idelalisib— uncovered
P53_PATHWAY0.080Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.070Inavolisib— uncovered
NOTCH_SIGNALING0.050Inavolisib— uncovered
APICAL_SURFACE0.040Temsirolimus— uncovered
INTERFERON_GAMMA_RESPONSE0.040Idelalisib— uncovered
SPERMATOGENESIS0.040Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.030Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.030Inavolisib— uncovered